1. A Broad and High-Tech Drug Portfolio with a Short Time-to-Market

• Lipigon is developing drugs for diseases caused by disruptions in the body's fat metabolism, where adequate treatment is currently lacking or limited, and where there is a significant unmet need for new and effective drugs.

• Initially, Lipigon is focusing on development towards advanced diseases, niche conditions, or genetically defined patient segments where it is possible to identify treatment effects early in clinical development. An early identification of treatment efficacy during clinical development, paves the way for smaller patient trials, shorter development timelines, and reduced overall development costs, consequently minimizing developmental risks.

• In some cases, there is the potential for orphan drug status to further mitigate development risk and establish conditions for market exclusivity and attractive pricing.

• In the long term, there is potential to expand the indication area to include more common diseases caused by disruptions in the body's management of fats.

2. Substantial and Growing Medical Need in Lipigon's Fat-Related Disease Areas

• Cardiovascular diseases have long been the leading cause of mortality and morbidity in the Western world. Even in developing countries, there is an increasing prevalence of these lifestyle-related diseases, corresponding with an improved standard of living.

• Lipigon's initial focus is on several niche markets within the broader pharmaceutical market dedicated to lipid regulation. These markets consist of smaller patient populations with a significant demand for new medications.

• Current treatments often prove inadequate. For many diseases, there is a lack of treatments that are sufficiently safe or effective.

3. Dynamic Research Fields with Robust M&A Activity

• Lipigon stands at the forefront of research within one of the world's most extensive disease domains. Collaborations with renowned companies such as AstraZeneca, HitGen, CombiGene, and Secarna validate the company's scientific excellence.

• In Lipigon's domain, there is a high level of merger and acquisition (M&A) activity, with several groundbreaking deals in recent years, even in the early stages of development. This can be attributed to a growing interest in advanced treatment approaches, combined with an increased awareness among major pharmaceutical players of the persistent medical needs in this area.

• The three projects under Lipigon's control target attractive end markets, each with a minimum estimated value of at least USD 1 billion.

4. Esteemed Ownership and a Competent Leadership and Board

• Lipigon is backed by a leadership team with over 100 years of combined experience in pharmaceutical development and corporate governance within the biotech sector. The company possesses significant expertise in early-stage development, clinical development, business development, and financial matters.

• The board of directors is distinguished by its high-level scientific expertise and extensive experience in pharmaceutical development, business expansion, financing, business law, and entrepreneurship within the life sciences industry.